Drugs / biphasic human insulin 30
biphasic human insulin 30
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00825253 | Mar → May 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01526980 | May → Nov 2002 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00799448 | Sep 2003 → Sep 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | biphasic human insulin 30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00799448 ↗ |
| Known as | BHI | “with biphasic human insulin (BHI, 30/70) twice daily in adults with type 2 diabetes already treated with insulin” PMID 19527481 ↗ Jul 2009 |
| Known as | BHI 30 | “Study 1 consisted of BIAsp 30 OD, b.i.d., and t.i.d. versus biphasic human insulin 30/70 (BHI 30), OD (n = 24).” PMID 19487640 ↗ Jun 2009 |
| Known as | biphasic human insulin 30/70 | “Study 1 consisted of BIAsp 30 OD, b.i.d., and t.i.d. versus biphasic human insulin 30/70 (BHI 30), OD (n = 24).” PMID 19487640 ↗ Jun 2009 |
| Route | Subcutaneous | “Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period” NCT01526980 ↗ |